Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
Ofatumumab is a drug that works by attaching to the CD20 molecule found on the surface of
cancerous B cells, and then triggering the death of those cells. It is approved by the FDA
for treatment of another B-cell cancer, chronic lymphocytic leukemia, and also has evidence
of success in people who's B-cell lymphomas have relapsed after initial treatments. In this
research study we are looking to see if ofatumumab is effective and safe in treating
previously untreated B-cell NHL.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Beth Israel Deaconess Medical Center Dana-Farber Cancer Institute GlaxoSmithKline